Clinical Trial: Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Prospective Study of Frontline Helicobacter Pylori Eradication Therapy in the Treatment of Early-stage Extragastric Mucosa-associated Lymphoid Tissue Lymphoma

Brief Summary: Gastric low-grade mucosa-associated lymphoid tissue lymphoma (MALToma) is associated with Helicobacter pylori (HP) infection, and around 70% of these tumors can be cured by HP eradication therapy (HPE). However, the role of antibiotics in the frontline treatment of extragastric MALToma remains unclear. In addition to anecdotal case reports showing histologic regression of extragastric MALTomas after antibiotics, our explorative study found that frontline HPE (clarithromycin, amoxicillin, and omeprazole) resulted in complete remission (CR) in this subgroup patients (2 salivary gland, 1 lung, 1 colon, and 4 ocular adnexal MALToma [OAML]). Interestingly, two patients with OAML who do not respond to Chlamydia psittaci (CP) eradication using doxycycline achieved CR after HPE. These findings suggest that bacterial infections, including HP, may be involved in the lymphomagenesis of these extragastric MALTomas. Our preliminary results also revealed that 5 (23.8%) of 21 HP-negative gastric MALToma patients achieved CR after HPE, indicating that antibiotics may also have ability to eradicate non-HP bacteria. Based on our preliminary findings and the indolent biologic behavior of MALToma, it is reasonable to use frontline HPE in the treatment of early-stage low-grade extragastric MALToma.

Detailed Summary:

Through a prospective trial of frontline HPE in the treatment of early-stage extragastric MALToma, investigators will evaluate and investigate the following issues:

  1. The CR and partial remission (PR) rate for antibiotics as 1st-line therapy for stage IE and stage IIE extragastric MALToma
  2. The durability of CR and PR (relapse-free survival) after antibiotics treatment (HPE) in early-stage extragastric MALToma
  3. The assessment of the evidence of bacterial infection, such as HP, in extragastric MALToma.
  4. The identification of potential biomarkers that help us predict whether extragastric MALToma can respond to frontline HPE.

Sponsor: National Taiwan University Hospital

Current Primary Outcome: The complete and partial remission rate for antibiotics as 1st-line therapy for stage IE-IIE1 extragastric MALT lymphoma. [ Time Frame: 5 years ]

The complete remission rate and partial remission rate for antibiotics (HP eradicaiton) as 1st-line therapy for early-stage extragastric MALT lymphoma


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • The overall survival of early-stage extragastric MALT lymphoma patients who received frontline HP eradication therapy [ Time Frame: 5 years ]
  • The assessment of the evidence of bacterial infection in all extragstric MALT lymphoma [ Time Frame: 5 years ]
  • The usefulness of pattern of NF-κB, BCL10, BAFF, API2-MALT1, and IgH-MALT1 by IHC staining or FISH in prospectively predicting the antibiotics responsiveness of extragastric MALT lymphoma [ Time Frame: 5 years ]
  • The relapse-free survival of early-stage extragastric MALT lymphoma patients who received antibiotics as 1st-line therapy [ Time Frame: 5 years ]


Original Secondary Outcome: Same as current

Information By: National Taiwan University Hospital

Dates:
Date Received: December 1, 2016
Date Started: February 2016
Date Completion: December 2019
Last Updated: December 6, 2016
Last Verified: December 2016